Yibin Deng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yibin Deng has a total of 117 co-authors. Here are the top co-authors by number of shared publications:
- Huabing Chen
Department of Pharmacy, The First Affiliated Hospital, and College of Pharmaceutical Sciences, Suzhou Medical College, Soochow University, Suzhou 215006, China
20 shared publications Hengte Ke
Jiangsu Key Laboratory of Neuropsychiatric Diseases, and College of Pharmaceutical Sciences, Soochow University, Suzhou 215123, China
12 shared publicationsTao Yang
Jiangsu Key Laboratory of Neuropsychiatric Diseases, and College of Pharmaceutical Sciences, Soochow University, Suzhou 215123, China
10 shared publicationsAijun Zhu
School of Radiological and Interdisciplinary Sciences (RAD-X), Collaborative Innovation Center of Radiation Medicine of Jiangsu Higher Education Institutions, and School of Radiation Medicine and Protection, and ‡Jiangsu Key Laboratory of Translational Research and Therapy for Neuro-Psycho-Diseases, College of Pharmaceutical Sciences, Soochow University , Suzhou 215123, China
6 shared publicationsHong Yang
School of Radiological and Interdisciplinary Sciences (RAD-X), Collaborative Innovation Center of Radiation Medicine of Jiangsu Higher Education Institutions, and School of Radiation Medicine and Protection, and ‡Jiangsu Key Laboratory of Translational Research and Therapy for Neuro-Psycho-Diseases, College of Pharmaceutical Sciences, Soochow University , Suzhou 215123, China
6 shared publicationsYitian Chen
Institute for Interdisciplinary Drug Research and Translational Sciences, Jiangsu Key Laboratory of Drug Discovery and Translational Research for Brain Diseases, Jiangsu Province Engineering Research Center of Precision Diagnostics and Therapeutics Development, College of Pharmaceutical Sciences, Engineering Research Center of RNA Medicine and Cell Therapy Technology, Ministry of Education, Suzhou Medical College, Soochow University, Suzhou 215123, China
6 shared publications
Latest Publications
- 27 June 2026
- Published by Elsevier in Journal of Controlled Release
- Vol. 397, 115141
A bone-marrow-homing biomimetic STING nanoinhibitor alleviates radiation-induced hematopoietic injury via modulating macrophage polarization
- 27 June 2026
- Published by Elsevier in Journal of Controlled Release
- Vol. 397, 115141
A bone-marrow-homing biomimetic STING nanoinhibitor alleviates radiation-induced hematopoietic injury via modulating macrophage polarization
- 9 January 2026
- Published by Elsevier in Science Bulletin
- Vol. 71 (4) , 795-807
Photo-responsive polyprodrug supramolecular assemblies with self-accelerated subcellular delivery for synergistic photochemotherapy
- 9 January 2026
- Published by Elsevier in Science Bulletin
- Vol. 71 (4) , 795-807
Photo-responsive polyprodrug supramolecular assemblies with self-accelerated subcellular delivery for synergistic photochemotherapy
- 30 March 2025
- Published by Elsevier in Journal of Controlled Release
- Vol. 382, 113667
Breaking the barriers in effective and safe Toll-like receptor stimulation via nano-immunomodulators for potent cancer immunotherapy
- 30 March 2025
- Published by Elsevier in Journal of Controlled Release
- Vol. 382, 113667
Breaking the barriers in effective and safe Toll-like receptor stimulation via nano-immunomodulators for potent cancer immunotherapy
- Open Access
- 14 December 2024
- Published by Elsevier in European Journal of Pharmaceutical Sciences
- Vol. 205, 106989
Nanoparticle-enabled In Situ drug potency activation for enhanced tumor-specific therapy
- 14 December 2024
- Published by Elsevier in European Journal of Pharmaceutical Sciences
- Vol. 205, 106989
Open AccessNanoparticle-enabled In Situ drug potency activation for enhanced tumor-specific therapy
- 6 July 2024
- Published by Elsevier in Journal of Controlled Release
- Vol. 372, 829-845
A bioinspired doxorubicin-carried albumin Nanocage against aggressive Cancer via systemic targeting of tumor and lymph node metastasis
- 6 July 2024
- Published by Elsevier in Journal of Controlled Release
- Vol. 372, 829-845
A bioinspired doxorubicin-carried albumin Nanocage against aggressive Cancer via systemic targeting of tumor and lymph node metastasis
- 31 December 2023
- Published by Springer Nature in Drug Delivery and Translational Research
- Vol. 14 (6) , 1708-1724
Bibliometric and visualized analysis of cancer nanomedicine from 2013 to 2023
Cancer nanomedicine has been an emerging field for drug development against malignant tumors during the past three decades. A bibliometric analysis was performed to characterize the current international trends and present visual representations of the evolution and emerging trends in the research and development of nanocarriers for cancer treatment. This study employed bibliometric analysis and visualization techniques to analyze the literature on antitumor nanocarriers published between 2013 and 2023. A total of 98,980 articles on antitumor nanocarriers were retrieved from the Web of Science Core Collection (WoSCC) database and analyzed using the Citespace software for specific characteristics such as publication year, countries/regions, organizations, keywords, and references. Network visualization was constructed by VOSviewer and Citespace. From 2013 to 2023, the annual global publications increased 7.39 times, from 1851 to 13,683. People’s Republic of China (2588 publications) was the most productive country. Chinese Academy of Sciences (298 publications) was the most productive organization. The top 5 high-frequency keywords were “nanoparticles,” “drug delivery,” “nanomedicine,” “cancer,” and “nanocarriers.” The keywords with the strongest citation bursts recently were “cancer immunotherapy,” “microenvironment,” “antitumor immunity,” etc., which indicated the emerging frontiers of antitumor nanomedicine. The co-occurrence cluster analysis of the keywords formed 6 clusters, and most of the top 10 publications by citation counts focused on cluster #1 (nanocarriers) and cluster #2 (cancer immunotherapy). We further provided insightful discussions into the identified subtopics to help researchers gain more details of current trends and hotspots in this field. The present study processes a macro-level literature analysis of antitumor nanocarriers and provides new perspectives and research directions for future development in cancer nanomedicine. Graphical Abstract
- 31 December 2023
- Published by Springer Nature in Drug Delivery and Translational Research
- Vol. 14 (6) , 1708-1724
Bibliometric and visualized analysis of cancer nanomedicine from 2013 to 2023
Cancer nanomedicine has been an emerging field for drug development against malignant tumors during the past three decades. A bibliometric analysis was performed to characterize the current international trends and present visual representations of the evolution and emerging trends in the research and development of nanocarriers for cancer treatment. This study employed bibliometric analysis and visualization techniques to analyze the literature on antitumor nanocarriers published between 2013 and 2023. A total of 98,980 articles on antitumor nanocarriers were retrieved from the Web of Science Core Collection (WoSCC) database and analyzed using the Citespace software for specific characteristics such as publication year, countries/regions, organizations, keywords, and references. Network visualization was constructed by VOSviewer and Citespace. From 2013 to 2023, the annual global publications increased 7.39 times, from 1851 to 13,683. People’s Republic of China (2588 publications) was the most productive country. Chinese Academy of Sciences (298 publications) was the most productive organization. The top 5 high-frequency keywords were “nanoparticles,” “drug delivery,” “nanomedicine,” “cancer,” and “nanocarriers.” The keywords with the strongest citation bursts recently were “cancer immunotherapy,” “microenvironment,” “antitumor immunity,” etc., which indicated the emerging frontiers of antitumor nanomedicine. The co-occurrence cluster analysis of the keywords formed 6 clusters, and most of the top 10 publications by citation counts focused on cluster #1 (nanocarriers) and cluster #2 (cancer immunotherapy). We further provided insightful discussions into the identified subtopics to help researchers gain more details of current trends and hotspots in this field. The present study processes a macro-level literature analysis of antitumor nanocarriers and provides new perspectives and research directions for future development in cancer nanomedicine. Graphical Abstract
- 9 November 2023
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 20 (12) , 6345-6357
Long-Acting Nanohybrid Hydrogel Induces Persistent Immunogenic Chemotherapy for Suppressing Postoperative Tumor Recurrence and Metastasis
Despite the continuous advancement of surgical resection techniques, postoperative tumor recurrence and metastasis remain a huge challenge. Here, we constructed an injectable curcumin/doxorubicin-loaded nanoparticle (NanoCD) hydrogel, which could effectively inhibit tumor regrowth and metastasis via reshaping the tumor immune microenvironment (TIME) for highly effective postsurgical cancer treatment. NanoCD was prepared by the controlled assembly of curcumin (CUR) and doxorubicin (DOX) via π-π stacking and hydrogen bonding in the presence of human serum albumin. To facilitate prolonged treatment of postsurgical tumors, NanoCD was further incorporated into the temperature-sensitive Poloxamer 407 gel (NanoCD@Gel) for intracavity administration. Mechanistically, DOX induced the generation of intracellular reactive oxygen species (ROS) and CUR reduced the ROS metabolism by inhibiting thioredoxin reductase (TrxR). The synergy of DOX and CUR amplified intracellular ROS levels and thus resulted in enhanced immunogenic cell death (ICD) of tumor cells. Upon being injected into the tumor cavity after resection, the in situ-generated NanoCD@Gel allowed the local release of CUR and DOX in a controlled manner to induce local chemotherapy and persistently activate the antitumor immune response, thereby achieving enhanced immunogenic chemotherapy with reduced systemic toxicity. Our work provides an elegant strategy for persistently stimulating effective antitumor immunity to prevent postsurgical tumor recurrence and metastasis.
- 9 November 2023
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 20 (12) , 6345-6357
Long-Acting Nanohybrid Hydrogel Induces Persistent Immunogenic Chemotherapy for Suppressing Postoperative Tumor Recurrence and Metastasis
Despite the continuous advancement of surgical resection techniques, postoperative tumor recurrence and metastasis remain a huge challenge. Here, we constructed an injectable curcumin/doxorubicin-loaded nanoparticle (NanoCD) hydrogel, which could effectively inhibit tumor regrowth and metastasis via reshaping the tumor immune microenvironment (TIME) for highly effective postsurgical cancer treatment. NanoCD was prepared by the controlled assembly of curcumin (CUR) and doxorubicin (DOX) via π-π stacking and hydrogen bonding in the presence of human serum albumin. To facilitate prolonged treatment of postsurgical tumors, NanoCD was further incorporated into the temperature-sensitive Poloxamer 407 gel (NanoCD@Gel) for intracavity administration. Mechanistically, DOX induced the generation of intracellular reactive oxygen species (ROS) and CUR reduced the ROS metabolism by inhibiting thioredoxin reductase (TrxR). The synergy of DOX and CUR amplified intracellular ROS levels and thus resulted in enhanced immunogenic cell death (ICD) of tumor cells. Upon being injected into the tumor cavity after resection, the in situ-generated NanoCD@Gel allowed the local release of CUR and DOX in a controlled manner to induce local chemotherapy and persistently activate the antitumor immune response, thereby achieving enhanced immunogenic chemotherapy with reduced systemic toxicity. Our work provides an elegant strategy for persistently stimulating effective antitumor immunity to prevent postsurgical tumor recurrence and metastasis.
- Open Access
- 29 April 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-25
Nanoparticle-mediated TRPV1 channel blockade amplifies cancer thermo-immunotherapy via heat shock factor 1 modulation
The survival of malignant tumors is highly dependent on their intrinsic self-defense pathways such as heat shock protein (HSP) during cancer therapy. However, precisely dismantling self-defenses to amplify antitumor potency remains unexplored. Herein, we demonstrate that nanoparticle-mediated transient receptor potential vanilloid member 1 (TRPV1) channel blockade potentiates thermo-immunotherapy via suppressing heat shock factor 1 (HSF1)-mediated dual self-defense pathways. TRPV1 blockade inhibits hyperthermia-induced calcium influx and subsequent nuclear translocation of HSF1, which selectively suppresses stressfully overexpressed HSP70 for enhancing thermotherapeutic efficacy against a variety of primary, metastatic and recurrent tumor models. Particularly, the suppression of HSF1 translocation further restrains the transforming growth factor β (TGFβ) pathway to degrade the tumor stroma, which improves the infiltration of antitumor therapeutics (e.g. anti-PD-L1 antibody) and immune cells into highly fibrotic and immunosuppressive pancreatic cancers. As a result, TRPV1 blockade retrieves thermo-immunotherapy with tumor-eradicable and immune memory effects. The nanoparticle-mediated TRPV1 blockade represents as an effective approach to dismantle self-defenses for potent cancer therapy.
- 29 April 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-25
Open AccessNanoparticle-mediated TRPV1 channel blockade amplifies cancer thermo-immunotherapy via heat shock factor 1 modulation
The survival of malignant tumors is highly dependent on their intrinsic self-defense pathways such as heat shock protein (HSP) during cancer therapy. However, precisely dismantling self-defenses to amplify antitumor potency remains unexplored. Herein, we demonstrate that nanoparticle-mediated transient receptor potential vanilloid member 1 (TRPV1) channel blockade potentiates thermo-immunotherapy via suppressing heat shock factor 1 (HSF1)-mediated dual self-defense pathways. TRPV1 blockade inhibits hyperthermia-induced calcium influx and subsequent nuclear translocation of HSF1, which selectively suppresses stressfully overexpressed HSP70 for enhancing thermotherapeutic efficacy against a variety of primary, metastatic and recurrent tumor models. Particularly, the suppression of HSF1 translocation further restrains the transforming growth factor β (TGFβ) pathway to degrade the tumor stroma, which improves the infiltration of antitumor therapeutics (e.g. anti-PD-L1 antibody) and immune cells into highly fibrotic and immunosuppressive pancreatic cancers. As a result, TRPV1 blockade retrieves thermo-immunotherapy with tumor-eradicable and immune memory effects. The nanoparticle-mediated TRPV1 blockade represents as an effective approach to dismantle self-defenses for potent cancer therapy.
- 9 September 2022
- Published by Elsevier in Journal of Controlled Release
- Vol. 350, 761-776
Self-activated arsenic manganite nanohybrids for visible and synergistic thermo/immuno-arsenotherapy
- 9 September 2022
- Published by Elsevier in Journal of Controlled Release
- Vol. 350, 761-776
Self-activated arsenic manganite nanohybrids for visible and synergistic thermo/immuno-arsenotherapy
- 5 July 2021
- Published by Wiley in Advanced Materials
- Vol. 33 (32) , 2100795
Highly Efficient Far‐Red/NIR‐Absorbing Neutral Ir(III) Complex Micelles for Potent Photodynamic/Photothermal Therapy
A critical issue in photodynamic therapy (PDT) is inadequate reactive oxygen species (ROS) generation in tumors, causing inevitable survival of tumor cells that usually results in tumor recurrence and metastasis. Existing photosensitizers frequently suffer from relatively low light‐to‐ROS conversion efficiency with far‐red/near‐infrared (NIR) light excitation due to low‐lying excited states that lead to rapid non‐radiative decays. Here, a neutral Ir(III) complex bearing distyryl boron dipyrromethene (BODIPY‐Ir) is reported to efficiently produce both ROS and hyperthermia upon far‐red light activation for potentiating in vivo tumor suppression through micellization of BODIPY‐Ir to form “Micelle‐Ir”. BODIPY‐Ir absorbs strongly at 550–750 nm with a band maximum at 685 nm, and possesses a long‐lived triplet excited state with sufficient non‐radiative decays. Upon micellization, BODIPY‐Ir forms J‐type aggregates within Micelle‐Ir, which boosts both singlet oxygen generation and the photothermal effect through the high molar extinction coefficient and amplification of light‐to‐ROS/heat conversion, causing severe cell apoptosis. Bifunctional Micelle‐Ir that accumulates in tumors completely destroys orthotopic 4T1 breast tumors via synergistic PDT/photothermal therapy (PTT) damage under light irradiation, and enables remarkable suppression of metastatic nodules in the lungs, together without significant dark cytotoxicity. The present study offers an emerging approach to develop far‐red/NIR photosensitizers toward potent cancer therapy.
- 5 July 2021
- Published by Wiley in Advanced Materials
- Vol. 33 (32) , 2100795
Highly Efficient Far‐Red/NIR‐Absorbing Neutral Ir(III) Complex Micelles for Potent Photodynamic/Photothermal Therapy
A critical issue in photodynamic therapy (PDT) is inadequate reactive oxygen species (ROS) generation in tumors, causing inevitable survival of tumor cells that usually results in tumor recurrence and metastasis. Existing photosensitizers frequently suffer from relatively low light‐to‐ROS conversion efficiency with far‐red/near‐infrared (NIR) light excitation due to low‐lying excited states that lead to rapid non‐radiative decays. Here, a neutral Ir(III) complex bearing distyryl boron dipyrromethene (BODIPY‐Ir) is reported to efficiently produce both ROS and hyperthermia upon far‐red light activation for potentiating in vivo tumor suppression through micellization of BODIPY‐Ir to form “Micelle‐Ir”. BODIPY‐Ir absorbs strongly at 550–750 nm with a band maximum at 685 nm, and possesses a long‐lived triplet excited state with sufficient non‐radiative decays. Upon micellization, BODIPY‐Ir forms J‐type aggregates within Micelle‐Ir, which boosts both singlet oxygen generation and the photothermal effect through the high molar extinction coefficient and amplification of light‐to‐ROS/heat conversion, causing severe cell apoptosis. Bifunctional Micelle‐Ir that accumulates in tumors completely destroys orthotopic 4T1 breast tumors via synergistic PDT/photothermal therapy (PTT) damage under light irradiation, and enables remarkable suppression of metastatic nodules in the lungs, together without significant dark cytotoxicity. The present study offers an emerging approach to develop far‐red/NIR photosensitizers toward potent cancer therapy.